Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 12/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.59 |
| ▸ | HRH2 | P25021 | 2/20 | 0.37 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | KHK | P50053 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13650445 | 0.89 | HRH4 (0.62) | HRH4HRH3HRH2MAP2K7 | |
| SCHEMBL13650450 | 0.87 | HRH4 (0.61) | HRH4HRH3HRH2MAP2K7DHFR | |
| SCHEMBL13650622 | 0.85 | HRH4 (0.56) | HRH4HRH3HRH2MAP2K7DHFR | |
| SCHEMBL13654396 | 0.84 | HRH4 (0.68) | HRH4HRH3HRH2MAP2K7DHFR | |
| SCHEMBL13650452 | 0.84 | HRH4 (0.61) | HRH4HRH3HRH2 | |
| SCHEMBL13650444 | 0.83 | HRH4 (0.63) | HRH4HRH3HRH2HRH1 | |
| SCHEMBL13650477 | 0.82 | HRH4 (0.66) | HRH4HRH3HRH2MAP2K7DHFR | |
| SCHEMBL13650455 | 0.82 | HRH4 (0.59) | HRH4HRH3HRH2 | |
| SCHEMBL13650471 | 0.82 | HRH4 (0.64) | HRH4HRH3HRH2MAP2K7HRH1 | |
| SCHEMBL13650490 | 0.82 | HRH4 (0.64) | HRH4HRH3HRH2MAP2K7DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436005-B2 | Macrocyclic pyrimidine derivatives | ABBOTT LABORATORIES (US) | 2013-05-07 | — | — | US | disclosed |
| WO-2009123967-A1 | 5,6,7,8-TETRAHYDROQUINAZOLIN-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H4 RECEPTOR MODULATORS FOR THE TREATMENT OF ASTHMA | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20090253678-A1 | MACROCYCLIC PYRIMIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090253678-A1 | MACROCYCLIC PYRIMIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253678-A1 | MACROCYCLIC PYRIMIDINE DERIVATIVES | DPYD, TYMS, TYMP | HRH4 3370/4885HRH3 3555/4885HRH2 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.